NASDAQ · ALGS
Aligos Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALGS: Nov 5, 2026
Aligos Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.43. The reported EPS for the same quarter last year was $-3.04.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.43 | $-2.06 | $-2.81 | 2 |
| Dec 2026 | $-1.91 | $-1.80 | $-2.02 | 2 |
| Mar 2027 | $-1.64 | $-1.49 | $-1.79 | 2 |
| Jun 2027 | $-1.64 | $-1.50 | $-1.78 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel- RTTNews · Oct 6, 1:25 AM EDTAligos Therapeutics To Present HBV, HDV Programs At AASLD 2026(RTTNews) – Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company, announced that five abstracts have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, being held November 5 – 9, 2026.
- RTTNews · Aug 10, 11:41 AM EDTAligos Therapeutics Jumps 28% As Pevifoscorvir Advances Toward 2027 Phase 2 Data(RTTNews) – Shares of Aligos Therapeutics, Inc. (ALGS) are up 26.99% today. The company recently provided an update on its pipeline and reported its second-quarter 2026 financial results, with investors focusing on progress in its chronic hepatitis B programs and strengthened non
- RTTNews · Jul 13, 10:47 AM EDTAligos Completes Enrollment In Phase 2 Trial Of Pevifoscorvir Sodium For HBV; Stock Down(RTTNews) – Aligos Therapeutics, Inc. (ALGS), a clinical-stage biopharmaceutical company, announced on Monday that it has completed enrollment in both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) cohorts of the Phase 2 B-SUPREME trial in adults with chronic hepatitis B virus, or HBV
- RTTNews · Jul 7, 1:00 AM EDTAligos Secures $25M Upfront In Greater China HBV Deal; Stock Up(RTTNews) – Aligos Therapeutics, Inc. (ALGS) announced it has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. under an exclusive license agreement for Pevifoscorvir sodium in Greater China.
- Fintel · May 28, 8:02 PM EDTLake Street Initiates Coverage of Aligos Therapeutics (ALGS) with Buy RecommendationFintel reports that on May 28, 2026, Lake Street initiated coverage of Aligos Therapeutics (NasdaqCM:ALGS) with a Buy recommendation. Analyst Price Forecast Suggests 1,098.50% Upside
- RTTNews · May 27, 8:47 AM EDTAligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B(RTTNews) – Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic hepatitis B and other ongoing studies at the European Association for the Study
- Fintel · May 21, 8:02 PM EDTCantor Fitzgerald Initiates Coverage of Aligos Therapeutics (ALGS) with Overweight RecommendationFintel reports that on May 21, 2026, Cantor Fitzgerald initiated coverage of Aligos Therapeutics (NasdaqCM:ALGS) with a Overweight recommendation. Analyst Price Forecast Suggests 1,098.50% Upside
- RTTNews · May 8, 4:03 AM EDTAligos Therapeutics Posts Narrower Q1 Loss, Highlights Pipeline Progress; Stock Up(RTTNews) – Aligos Therapeuitcs, Inc. (ALGS) has reported first-quarter 2026 financial results, narrowing its net loss while advancing multiple clinical programs in liver and viral diseases.
- Fintel · Apr 28, 12:20 AM EDTAligos Therapeutics (ALGS) Price Target Increased by 70.91% to 67.12The average one-year price target for Aligos Therapeutics (NasdaqCM:ALGS) has been revised to $67.12 / share. This is an increase of 70.91% from the prior estimate of $39.27 dated April 12, 2026. The price target is an average of many targets provided by analy
- RTTNews · Apr 24, 12:42 PM EDTAligos Therapeutics Grants Equity Awards To New Employees Under Nasdaq Rule 5635 (c)(4), Stock Up(RTTNews) – Aligos Therapeutics, Inc. (ALGS) has granted stock options to newly hired employees as part of inducement awards approved under Nasdaq Listing Rule 5635(c)(4), the company announced Friday.
- RTTNews · Apr 15, 9:59 AM EDTAligos Interim Analysis Supports HBV Program, Fast Track Granted(RTTNews) – Aligos Therapeutics, Inc. (ALGS) announced encouraging first interim results from its Phase 2 B-SUPREME study of Pevifoscorvir sodium in adults with chronic hepatitis B virus (HBV) infection.
- Fintel · Mar 26, 8:04 PM EDTWestPark Capital Initiates Coverage of Aligos Therapeutics (ALGS) with Buy RecommendationFintel reports that on March 26, 2026, WestPark Capital initiated coverage of Aligos Therapeutics (NasdaqCM:ALGS) with a Buy recommendation. Analyst Price Forecast Suggests 888.12% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aligos Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.